Toxicity T cell position vaccine of the cell for treating Hepatitis B and the preparing method

A technology for cytotoxicity and hepatitis B, applied in antiviral agents, pharmaceutical formulations, antibody medical components, etc., can solve the problems of incomplete elimination of viruses and poor long-term curative effect, and achieve the effect of enhancing cellular immune response and promoting activation
CN101036784AInactive Publication Date: 2007-09-19SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Publication Date
2007-09-19
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to bio-pharmaceutical engineer technology domain. At present, the therapeutic drugs for HBV infection mainly depend on IFN-Alpha and nucleotide analog, which can not kill virus thoroughly with worse remote therapeutic effect. The invention provides a cytotoxic T cell epitope vaccine for hepatitis B, comprising a fused polypeptide formed by connecting 21 CTL epitopes selected from CTL epitopes data of HBV antigen and two universal epitopes of auxiliary T lymphocyte. Saccharomyces Serevisiae is selected to express the fused antigen and mixes with immunologic adjvant. The said vaccine can activate and enhance the cellular immune response of patient with chronic HBV infection. The vaccine can also promote the immune elimination of HBV, and can be used for treatment of chronic hepatitis B.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field:

[0001] The invention relates to the technical field of biomedical engineering, and is a hepatitis B therapeutic cytotoxic T cell epitope vaccine and a preparation method thereof. Background technique:

[0002] Hepatitis B virus (HBV) is a hepatotropic DNA virus that is prone to chronic infection after infecting the human body. It is the first cause of liver cirrhosis and primary liver cancer in Southeast Asian countries and regions, including my country. The treatment drugs for HBV infection currently mainly rely on IFN-α and nucleoside analogues. None of these drugs can completely eliminate the virus, and the long-term efficacy is poor. Therapeutic vaccine is a specific immunotherapy that has emerged in the past decade. Animal and clinical studies have shown that vaccination of such vaccines can enhance the cellular immune response of the infected person (or animal), thereby inhibiting virus replication. Summary of the invention:

[0003] The purpose of the pre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More